Heavily Funded Biosplice Dumps Its Hair Loss Treatment

February 9, 2022

Heavily funded but small-in-size biotech Biosplice has scrapped dalosirvat, its treatment for hair loss in men, which was in late-stage development.

The company also laid off about 25 percent of its workforce as of Feb. 8, including 41 people from its clinical operations team.

Formerly known as Samumed, Biosplice raised a whopping $438 million in 2018 (some of that from Ikea’s venture arm) and another $120 million in April 2021. Its research has been focused on arthritis, hair loss and cancer.

View today's stories